ArticleCytotherapy2021

Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy.

Jeffrey Mao-Hwa Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.